Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Chlorphenesin Carbamate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Oncocross | CytoGen
Deal Size : Inapplicable
Deal Type : Inapplicable
Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer
Details : Chlorphenesin Carbamate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 19, 2021
Lead Product(s) : Chlorphenesin Carbamate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Oncocross | CytoGen
Deal Size : Inapplicable
Deal Type : Inapplicable